MedTrace Logo

Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

NCT04617626 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1735

Last updated 2021-07-20

No results posted yet for this study

Summary

The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality settings in Côte. The cross-sectional study will be carried out in conjunction with a single trachoma MDA in selected villages within one health district. Data on feasibility and acceptability will be collected through three main activities:

1. Analyses of existing routine monitoring, process, and adverse drug reaction data from the trachoma MDA platform into which the pilot activities are being integrated
2. A cross-sectional, post-MDA coverage survey
3. Qualitative data collection among targeting parents or primary caregivers of children ages 1 to 11 months in the pilot districts, and district-level MDA implementers, regarding the proposed azithromycin program.

Conditions

Interventions

DRUG

Azithromycin

Single dose of azithromycin suspension

Sponsors & Collaborators

  • National Program for the Fight Against Neglected Tropical Diseases, Côte d'Ivoire

    collaborator UNKNOWN

  • FHI 360

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
5 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04617626 on ClinicalTrials.gov